SOURCE:

https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf

To summarize this SOC, the search terms used seem to consist mainly of nonlethal conditions, yet **there were 96 deaths**. Herpes virus infections can cause a great deal of pain, which can be chronic and debilitating, and herpes eye infections have the potential to cause impaired vision or blindness. Yet, death other than from herpes encephalitis would be rare. However, encephalitis and encephalopathy are reported by Pfizer in different SOCs.

Certainly, multiple organ dysfunction syndrome can cause death in a significant number of cases, but only 18 were reported. **If all 18 led to death, from where did the other 78 deaths come?**

Inflammation types are not defined, but Pfizer has a separate SOC for Immune-Mediated/Autoimmune that would capture most of the purely inflammatory diseases. **So, we are left with no clarity or explanation for at least 78 deaths.**

Extremely high fevers can be lethal, and febrile seizures were reported by Pfizer in a separate SOC**. Of the 8,241 events, 8,207 were presented because each occurred six or more times.** What were the missing 34 events, and why were they not enumerated?

Finally, we are faced with the **15 individuals under 12 years of age (six of whom were infants), and nine adolescents** (with an unknown number of these less than age 16). **Pfizer's drug was not approved for those under age 16 at the time of 5.3.6 data collection, and the dosage given to these children and young people had not been determined.** We do not know how many deaths occurred in this underage group.

It is surprising that, in this SOC, **non-elderly adults had almost six times the number of adverse events seen in elderly adults**. In the first 90 days of rollout, priority for the vaccine was given to the elderly, high-risk patients, and health care workers. This distribution of adverse events is unexplained.

Despite the incomplete and inconsistent reporting

and 96 deaths,

Pfizer's conclusion remains the same:

"This cumulative case review does not raise new safety issues. Surveillance will continue."

Note: As of the date of this team report, no follow-up, updated, and comprehensive safety report (comparable to 5.3.6) has been publicly released.

Post-Marketing Team's CONCLUSION

RECALL this unsafe "vaccine."

Post Marketing Team